References
- Siegel RL, Miller KD, Jemal A. CA Cancer J Clin. 2017; 67:7–30.
- Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG; Cyclins and Cell Cycle Control in Cancer and Disease Genes Cancer. 2012; 3:649–57.
- Zhu XL, Wang Z, Lei WB, Zhuang H, Hou W, Wen Y et al. Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research 2012; 31:94.
- Hameed O and Humphrey PA. Immunohistochemistry in the diagnosis of minimal prostate cancer Current Diagnostic Pathology 2006; 12: 279–291.
- Omar H, Jack S and Peter H. Immunohistochemical Stains for p63 and α-Methylacyl-CoA Racemase, Versus a Cocktail Comprising Both, in the Diagnosis of Prostatic Carcinoma: A Comparison of the Immunohistochemical Staining of 430 Foci in Radical Prostatectomy and Needle Biopsy Tissues. American Journal of Surgical Pathology 2005; 29 (5): 579–587.
- Atta IS, Eid AG, El-Hag MA, AlQahtani FF. Can cyclin D1 be utilized as a second step “after basal cell marker” for both diagnosis and prognosis of prostatic adenocarcinoma? International Journal of Medical Science and Public Health 2016; 5(09).
- Gupta V, Garg M, Chaudhry M, Singh S, Sen R, Meenu Gill M et al. Role of cyclin D1 immunoreactivity and AgNOR staining in the evaluation of benign and malignant lesions of the prostate Prostate International 2014; 2; 21–30
- Khoo ML, Beasley NJ, Ezzat S J, Freeman L and Asa SL. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J. Clin. EndocrinolMetab 2002; 87: 1814–1818.
- Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, et al. DJ-1 binds androgen receptor directlyand mediates its activity in hormonally treated prostate cancer cells. Cancer Res 2007;67(10):4630–7.
- Mohammed AA. Biomarkers in prostate cancer: new era and prospective. Med Oncol. 2014; 31:140.
- Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, et al. Expression of cell cycle regulated genes and prostate cancer prognosis in a population-based cohort. Prostate. 2015 Sep; 75:1354–62.
- Knudsen K. E., Scher H. I. (2009) Clin. Cancer Res. 2009; 15, 4792–4798.
- Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000; 6:1891–1895.
- Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology. 2011; 58:781–789.
- Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol. 2000; 53:15–18.
- Ueda N, Yamashita M, Kuroda I, Takenaka I. Immunohistological evaluation of the expression of P27 and cyclin D1 in prostatic specimens. Nishinihon J Urol 2001; 63:246–9.
- Qahtani FF, Atta IS, Mady EA. P63 and Cyclin D 1 Expression in Benign Prostatic Hyperplasia versus Prostatic Adenocarcinoma: A Clinicopathologic, Radiologic, and Immunohistochemical Study. International Journal of Healthcare Sciences 2015; 2: 320–305.
- Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6:1891–1895.
- Kallakury B.V., Sheehan C.E., Ambros R.A., Kaufman H.A and Ross JS. The prognostic significance of p34 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997; 80: 753–763.
- Lev N, Roncevic D, Ickowicz D, Melamed E, Offen D. Role of DJ-1 in Parkinson’s disease. J Mol Neurosci. 2006; 29:215–25. Review. Erratum in: J Mol Neurosci. 2007; 31:307.
- Ismail IA, Kang HS, Lee HJ, Kim JK, Hong SH. DJ.1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer. 2014 Mar 4; 110:1298–306.
- Lisitskaia KV, Eremina LS, Ivanov AV, Kovaleva MA, Okhrits V, Toropygin IIu, et al. Study of DJ-1 protein in tissuespecimens cultured cells and serum of prostate cancer patients. Biomed Khim 2011;57:392–401.
- Osman W, Attia R and Abou Gabal H. DJ-1 and androgen receptor immunohistochemical expression in prostatic carcinoma: A possible role in carcinogenesis. Egypt Natio Can Inst J 2013; 25:223–230.
- Wang Q, Li F, Shi W, Zhang Q, Wang J, Yan X, et al. Overexpression of DJ-1 correlates with aggressive clinicopathological characteristics and poor prognosis in malignant tumors: a meta-analysis. Onco Targets Ther. 2018; 11:3931–3942.
- Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle. 2008; 7:1745–1762.
- Comstock CE, Revelo MR, Bunche CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer. 2007; 96: 970–979.
- Ozbek E, Mizrak B, Ozbek M, Buyukberber S, Davarci M. Cyclin-D1 protooncogen expression in prostate cancer. Turk J Cancer 2000; 30: 15–21
- Shiraishi T, Watanabe M, Muneyuki T, Nakayama, Morita J, Ito H, et al. clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol Int 1998; 61 p: 90–94
- Prahlad V. Raninga, Trapani G, Kathryn F. Cross talk between two antioxidant systems, Thioredoxin and DJ-1. Oncoscience 2014; 1 (1).
- Imrali A, Mao X, Yester-Velasco M. Shamash J, Lu Y. Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin. Am J Cancer Res 2016; 6:1772–1784.